| Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials P Mangtani, I Abubakar, C Ariti, R Beynon, L Pimpin, PEM Fine, ... Clinical infectious diseases 58 (4), 470-480, 2014 | 1093 | 2014 |
| ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19 S Mandal, J Barnett, SE Brill, JS Brown, EK Denneny, SS Hare, ... Thorax 76 (4), 396-398, 2021 | 1025 | 2021 |
| Interferon-γ release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis M Sester, G Sotgiu, C Lange, C Giehl, E Girardi, GB Migliori, A Bossink, ... European Respiratory Journal 37 (1), 100-111, 2010 | 757 | 2010 |
| Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study RA Evans, HJC McAuley, EM Harrison, A Shikotra, A Singapuri, M Sereno, ... The Lancet Respiratory Medicine 9 (11), 1275-1287, 2021 | 558 | 2021 |
| Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection RAM Breen, CJ Smith, H Bettinson, S Dart, B Bannister, MA Johnson, ... Thorax 59 (8), 704-707, 2004 | 474 | 2004 |
| Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis. I Abubakar, L Pimpin, C Ariti, R Beynon, P Mangtani, JAC Sterne, ... Health technology assessment (Winchester, England) 17 (37), 1, 2013 | 404 | 2013 |
| Drug-resistant tuberculosis: time for visionary political leadership I Abubakar, M Zignol, D Falzon, M Raviglione, L Ditiu, S Masham, I Adetifa, ... The Lancet infectious diseases 13 (6), 529-539, 2013 | 375 | 2013 |
| Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers CI Bloom, CM Graham, MPR Berry, F Rozakeas, PS Redford, Y Wang, ... PloS one 8 (8), e70630, 2013 | 354 | 2013 |
| Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study RA Evans, OC Leavy, M Richardson, O Elneima, HJC McAuley, ... The Lancet Respiratory Medicine 10 (8), 761-775, 2022 | 349 | 2022 |
| Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy K Dheda, FC Lampe, MA Johnson, MC Lipman Journal of Infectious Diseases 190 (9), 1670-1676, 2004 | 294 | 2004 |
| Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America Antiretroviral Therapy Cohort Collaboration Clinical Infectious Diseases 41 (12), 1772-1782, 2005 | 292 | 2005 |
| Anticipating the impact of the COVID-19 pandemic on TB patients and TB control programmes T Togun, B Kampmann, NG Stoker, M Lipman Annals of clinical microbiology and antimicrobials 19, 1-6, 2020 | 289 | 2020 |
| MMP-1 drives immunopathology in human tuberculosis and transgenic mice P Elkington, T Shiomi, R Breen, RK Nuttall, CA Ugarte-Gil, NF Walker, ... The Journal of clinical investigation 121 (5), 1827-1833, 2011 | 287 | 2011 |
| Immune reconstitution and “unmasking” of tuberculosis during antiretroviral therapy SD Lawn, RJ Wilkinson, MCI Lipman, R Wood American journal of respiratory and critical care medicine 177 (7), 680-685, 2008 | 259 | 2008 |
| Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial A Story, RW Aldridge, CM Smith, E Garber, J Hall, G Ferenando, L Possas, ... The Lancet 393 (10177), 1216-1224, 2019 | 247 | 2019 |
| The transmission of Mycobacterium tuberculosis in high burden settings TA Yates, PY Khan, GM Knight, JG Taylor, TD McHugh, M Lipman, ... The Lancet infectious diseases 16 (2), 227-238, 2016 | 240 | 2016 |
| Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection RAM Breen, RF Miller, T Gorsuch, CJ Smith, A Schwenk, W Holmes, ... Thorax 61 (9), 791-794, 2006 | 240 | 2006 |
| Lymphocyte activation in HIV-1 infection. II. Functional defects of CD28− T cells NJ Borthwick, M Bofill, WM Gombert, AN Akbar, E Medina, K Sagawa, ... Aids 8 (4), 431-442, 1994 | 238 | 1994 |
| Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study RK Gupta, EM Harrison, A Ho, AB Docherty, SR Knight, M van Smeden, ... The Lancet Respiratory Medicine 9 (4), 349-359, 2021 | 237 | 2021 |
| Treatment of latent tuberculosis infection: an updated network meta-analysis D Zenner, N Beer, RJ Harris, MC Lipman, HR Stagg, MJ Van Der Werf Annals of internal medicine 167 (4), 248-255, 2017 | 236 | 2017 |
Ibrahim AbubakarUniversity College LondonVerified email at ucl.ac.uk
